## DisclosureEquityIncentivePlansTables

**Year Ended**

|  | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 |
| --- | --- | --- | --- |
| **  Summary of Stock Option and RSU Activity** | The following table summarizes our stock option and RSU activity:

                                                                                
Weighted-                         Weighted-              
                                                                 Weighted-      
Average                           Average                
                                                                 Average        
Remaining                         Grant                  
                                                                 Exercise       
Contractual                       Date Fair              
                                                                 Price          
Life (Years)                      Value                  
  Balance, December 31, 2016                     12,875,422      $96.50         
4,082,089      $              207.11  
  Granted                                         1,163,678      $310.13        
3,073,404      $              308.71  
  Exercised or released                          (2,324,871      $81.04         
(1,561,889      $              216.46  
  Cancelled                                        (833,204      $327.33        
(904,294      $              233.59  
  Balance, December 31, 2017                     10,881,025      $105.56        
5.3                4,689,310      $              265.43  
  Vested and expected to vest,                   10,881,025      $105.56        
5.3                4,689,310      $              265.43  
  Exercisable and vested, December 31, 2017       8,029,228      $77.56         
4.7
 |  |  |
| **  Schedule of Fair Value of Stock Option Award and ESPP on Grant Date** | We use the fair value method in recognizing stock-based compensation expense. 
Under the fair value method, we estimate the fair value of each stock option 
award and the ESPP on the grant date generally using the Black-Scholes option 
pricing model and the weighted-average assumptions in the following table:

                                        Year Ended December 31,                 
                                        2017                                    
2016                 2015              
 ───────────────────────────────────────────────────────────────────────────────
─────────────────────────────────────────
  Risk-free interest rate:                                                      
  Stock options                                                         1.8     
1.5                   1.6  
  ESPP                                                                  1.1     
0.6                   0.3  
  Expected term (in years):                                                     
  Stock options                                                         5.1     
6.2                   5.4  
  ESPP                                                                  0.5     
0.5                   0.5  
  Expected volatility:                                                          
  Stock options                                                          42     
47                    48  
  ESPP                                                                   35     
41                    42  
  Dividend yield:                                                               
  Stock options                                                         0.0     
0.0                   0.0  
  ESPP                                                                  0.0     
0.0                   0.0  
  Grant date fair value per share:                                              
  Stock options                         $                            122.25     
$         98.70      $         108.28  
  ESPP                                  $                             75.05     
$         51.31      $          58.77
 |  |  |
| **  Summary of Stock-Based Compensation Expense** | The following table summarizes our stock-based compensation expense by line item
in the consolidated statements of operations (in thousands):

                                           Year Ended December 31,              
                                           2017                                 
2016                   2015               
 ───────────────────────────────────────────────────────────────────────────────
────────────────────────────────────────────────
  Cost of sales                            $                             43,845 
$          30,400      $          19,244  
  Research and development                                              217,616 
154,632                 89,309  
  Selling, general and administrative                                   205,299 
149,193                 89,446  
  Total                                    $                            466,760 
$         334,225      $         197,999
 |  |  |